In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: Comparison of yeast-like and mycelial forms

被引:113
作者
Nakai, T
Uno, J
Ikeda, F
Tawara, S
Nishimura, K
Miyaji, M
机构
[1] Fujisawa Pharmaceut Co Ltd, Dept Infect Dis, Med Biol Res Labs, Yodogawa Ku, Osaka 5328514, Japan
[2] Chiba Univ, Pathogen Fungi & Microbial Toxicoses Res Ctr, Chuo Ku, Chiba 2608673, Japan
关键词
D O I
10.1128/AAC.47.4.1376-1381.2003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The characteristics of in vitro micafungin (FK463) antifungal activity against six species of dimorphic fungi were investigated in accordance with the NCCLS M27-A microdilution methods. MICs of micafungin, amphotericin B, itraconazole, and fluconazole for Histoplasma capsulatum var. capsulatum, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Penicillium marneffei, and Sporothrix schenckii were determined both for the yeast-like form and mycelial form. Coccidioides immitis was tested only in its mycelial form. We have clearly demonstrated that the in vitro activity of micafungin depends considerably on the growth form of dimorphic fungi. Micafungin exhibited potent activity against the mycelial forms of H. capsulatum, B. dermatitidis, and C. immitis (MIC range, 0.0078 to 0.0625 mug/ml), while it was very weakly active against their yeast-like forms (MIC range, 32 to >64 mug/ml). Micafungin was also more active against the mycelial forms than the yeast-like forms of Paracoccidioides brasiliensis, Penicillium marneffei, and S. schenckii. The MICs of amphotericin B were 2 to 5 dilutions lower for the mycelial forms than for the yeast-like forms of B. dermatitidis and Paracoccidioides brasiliensis. There was no apparent difference in the activity of itraconazole between the two forms. The MICs of fluconazole for the yeast-like forms were generally lower than those for the mycelial forms, and considerably so for B. dermatitidis. These results suggest that the growth form employed in antifungal susceptibility testing of dimorphic fungi can considerably influence the interpretation of results. At present, it cannot be judged whether micafungin has clinical usefulness for dimorphic fungus infections, since for most fungi it remains uncertain which growth form correlates better with therapeutic outcome. However, the results of this study warrant further investigations of micafungin as a therapeutic agent for infections caused by dimorphic fungi.
引用
收藏
页码:1376 / 1381
页数:6
相关论文
共 29 条
[1]   Emerging disease issues and fungal pathogens associated with HIV infection [J].
Ampel, NM .
EMERGING INFECTIOUS DISEASES, 1996, 2 (02) :109-116
[2]  
CHANDLAR FW, 1998, PATHOLOGY EMERGING I, V2, P115
[4]   COCCIDIOIDOMYCOSIS - FACTORS AFFECTING THE HOST-PARASITE INTERACTION [J].
DRUTZ, DJ ;
HUPPERT, M .
JOURNAL OF INFECTIOUS DISEASES, 1983, 147 (03) :372-390
[5]   Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts [J].
Espinel-Ingroff, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (10) :2950-2956
[6]   Clinical relevance of antifungal resistance [J].
EspinelIngroff, A .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 1997, 11 (04) :929-&
[7]   Update on antifungals targeted to the cell wall:: focus on β-1,3-glucan synthase inhibitors [J].
Georgopapadakou, NH .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (02) :269-280
[8]   HISTOPLASMOSIS - A TREATMENT UPDATE [J].
GOLDMAN, M .
CURRENT OPINION IN INFECTIOUS DISEASES, 1994, 7 (06) :667-670
[9]   Treatment of histoplasmosis with MK-991 (L-743,872) [J].
Graybill, JR ;
Najvar, LK ;
Montalbo, EM ;
Barchiesi, FJ ;
Luther, MF ;
Rinaldi, MG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (01) :151-153
[10]   Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis [J].
Ikeda, F ;
Wakai, Y ;
Matsumoto, S ;
Maki, K ;
Watabe, E ;
Tawara, S ;
Goto, T ;
Watanabe, Y ;
Matsumoto, F ;
Kuwahara, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (03) :614-618